Use of methotrexate in patients with scleroderma and mixed connective tissue disease

Clinical and Experimental Rheumatology

Volumn 28, Issue 5 SUPPL. 61, 2010, Pages

  Kowal Bielecka, O ^a   Distler, O ^b  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Methotrexate; Mixed connective tissue disease; Systemic sclerosis

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; HEMOGLOBIN; IMMUNOGLOBULIN G; STEROID;

ARTHRITIS; ARTICLE; CLINICAL PRACTICE; DISEASE DURATION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG FIBROSIS; MIXED CONNECTIVE TISSUE DISEASE; MOUTH ULCER; NONHUMAN; PANCYTOPENIA; POLYARTHRITIS; POLYMYOSITIS; PRIORITY JOURNAL; PROGNOSIS; SCLERODERMA; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE; ANTIINFLAMMATORY ACTIVITY; CAUSE OF DEATH; CREATININE CLEARANCE; DISEASE COURSE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; IMMUNOGLOBULIN BLOOD LEVEL; IN VITRO STUDY; INTERSTITIAL LUNG DISEASE; LEUKOCYTE COUNT; LUNG DIFFUSION CAPACITY; MULTICENTER STUDY (TOPIC); OPEN STUDY; PATHOGENESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SEX DIFFERENCE; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; THROMBOCYTE COUNT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTI-INFLAMMATORY AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; MIXED CONNECTIVE TISSUE DISEASE; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 78650556703     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. DISTLER O, GAY S: Scleroderma. Internist (Berl) 2010;5:30-8.
2. DISTLER J, KALDEN JR, DISTLER O: Undifferentiated connective tissue diseases, overlap syndromes, and mixed connective tissue disease. In: JWJ BIJLSMA EULAR (Ed.): Compendium on Rheumatic Diseases. London: BMJ, 2009, p. 244-56.
3. GAUJOUX-VIALA C, SMOLEN JS, LANDEWE R et al.: Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:1004-9.
4. STEEN VD, MEDSGER TA: Changes in causes of death in systemic sclerosis 1972-2003. Ann Rheum Dis 2007;66:940-4.
5. LEROY EC, MEDSGER TA Jr: Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-6.
6. ABRAHAM D, BEYER C, DISTLER J H W, DISTLER O: The pathogenesis of systemic sclerosis. In: O. DISTLER (Ed.): Scleroderma - modern aspects of pathogenesis, diagnosis, and therapy. Unimed Bremen 2009, pp. 24-33.
7. VAN DEN HOOGEN FH, BOERBOOMS AM, SWAAK AJ, RASKER JJ, VAN LIER HJ, VAN DE PUTTE LB: Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996;35:364-72.
8. POPE JE, BELLAMY N, SEIBOLD JR et al.: A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351-8.
9. JOHNSON SR, FELDMAN BM, POPE JE, TOMLINSON GA: Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma. J Rheumatol 2009;36:323-9.
10. KOWAL-BIELECKA O, VEALE DJ: DMARDs in systemic sclerosis: Do they exist? In: O. DISTLER (Ed.): Scleroderma - modern aspects of pathogenesis, diagnosis, and therapy. Unimed Bremen, 2009, p 90-7.
11. DERK CT, GRACE E, SHENIN M, NAIK M, SCHULZ S, XIONG W: A prospective openlabel study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology (Oxford) 2009;48:1595-9.
12. CLEMENTS PJ, LACHENBRUCH PA, STERZ M et al.: Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients. Arthritis Rheum 1993;36:75-83.
13. KOWAL-BIELECKA O, LANDEWÉ R, AVOUAC J et al.: EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68:620-8.
14. QUILLINAN NP, DENTON CP: Diseasemodifying treatment in systemic sclerosis: current status. Curr Opin Rheumatol 2009;21:636-41.
15. HUNZELMANN N, MOINZADEH P, GENTH E et al.: High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy. Arthritis Res Ther 2009;11: R30.
16. STEEN VD, MEDSGER TA Jr: Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998;41:1613-9.
17. KIM YJ, SONG M, RYU JC: Mechanisms underlying methotrexate-induced pulmonary toxicity. Expert Opin Drug Saf 2009;8:451-8.
18. ARAKAWA H, YAMASAKI M, KURIHARA Y, YAMADA H, NAKAJIMA Y: Methotrexate induced pulmonary injury: serial CT findings. J Thorac Imaging 2003;18:231-6
19. DISTLER O, PAP T, KOWAL-BIELECKA O et al.: Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum 2001;44:2665-78.
20. YOZAi K, SHIKATA K, SASAKI M et al.: Methotrexate prevents renal injury in experimental diabetic rats via anti-inflammatory actions. J Am Soc Nephrol 2005;16:3326-38.
21. OZGEN M, KOCA SS, ISIK A, OZERCAN IH: Methotrexate has no antifibrotic effect in bleomycin-induced experimental scleroderma. J Rheumatol 2010;37:678-9.
22. VAN DEN HOOGEN F H J, VAN DER KRAAN PM, BOERBOOMS A M T, VAN DEN BERG WB, VAN LIER H J J, VAN DE PUTTE L B A: Effects of methotrexate on glycosaminoglycan production by scleroderma fibroblasts in culture. Ann Rheum Dis 1993;52:758-61.
23. CHAN ES, CRONSTEIN BN: Adenosine in fibrosis. Mod Rheumatol 2010;20:114-22.
24. ROZENBAUM M, SLOBODIN G, BOULMAN N et al.: Therapeutic vignette: old and new drugs in mixed connective tissue disease. Isr Med Assoc J 2008;10:831-2.
25. KIM P, GROSSMAN JM: Treatment of mixed connective tissue disease. Rheum Dis Clin North Am 2005;31:549-65, viii.